Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Huang, Min; Haiderali, Amin; Fox, Grace E; Frederickson, Andrew M.; Cortés, Javier; Fasching, Peter A.; O’Shaughnessy, Joyce

doi:10.1007/s40273-021-01121-7

Cited by 14 publications

(17 citation statements)

References 69 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An SLR of 19 studies published between 2016 and 2021 reported significant reductions in Functional Assessment of Cancer Therapy—Breast scores in patients with TNBC compared to those with non-TNBC [ 17 ]. Furthermore, a clinically meaningful decrease in mean utility values was reported in patients experiencing a progressed disease state (EQ-5D-3L index 0.601) compared to those in a progression-free state (EQ-5D-3L index 0.715) [ 17 ]. Pembrolizumab was found to improve HRQoL relative to chemotherapy in PD-L1–positive patients with metastatic TNBC [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…Breast cancer is associated with a substantial economic burden that is largely driven by high treatment costs. A systematic review conducted in 2023 demonstrated substantial variation in the proportion of total cancer care costs attributable to anticancer drugs, from 7.5% (systemic therapies) to 75% (targeted therapy [bevacizumab]) [ 17 – 19 ]. For immune checkpoint inhibitors, a retrospective analysis of United States (US) Medicaid files demonstrated an increase in expenditure from 2.8 million US dollars (USD) (~2.58 million Swiss francs [CHF]) in 2011 to USD4.1 billion (CHF~3.78 billion) in 2021 across all cancer types [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…In a systematic literature review (SLR), including 20 studies from ten different countries, cumulative treatment costs increased from USD29,724 (currency year, 2015) (CHF~27,369) to USD62,108 (CHF~57,189) in patients with stage I versus stage IV breast cancer, respectively (exchange rate, as of January 2023: USD1 = CHF0.9208) [ 21 ]. The previously mentioned SLR published by Huang et al reported that mean per-patient annual direct medical costs for patients with TNBC ranged from USD20,000 to over USD100,000 (CHF~18,415–92,078) in patients with stage I–III TNBC and from USD100,000 to USD300,000 (CHF~92,078–276,187) in those with stage IV TNBC (exchange rate, as of January 2023: USD1 = CHF0.9208) [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Favre-Bulle,

Huang,

Haiderali

et al. 2023

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

Aim This study assessed the cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy plus placebo followed by adjuvant placebo for patients with high-risk, early-stage, triple-negative breast cancer (TNBC) from a Swiss third-party payer perspective over a lifetime horizon (51 years). Materials and Methods A transition model with four health states (event-free, locoregional recurrence, distant metastasis, and death) was developed to assess the cost-effectiveness of pembrolizumab plus chemotherapy versus chemotherapy alone for the treatment of high-risk, early-stage TNBC. Data were utilized from the KEYNOTE-522 randomized controlled trial (ClinicalTrials.gov, NCT03036488). The incremental cost-effectiveness ratio (ICER) was calculated, which was reported as cost per life year or quality-adjusted life year (QALY) gained. A one-way deterministic sensitivity analysis, a probabilistic sensitivity analysis (PSA) and scenario analyses were conducted to assess the robustness of the model results. Results Base-case results estimated an ICER of 14,114 Swiss francs (CHF)/QALY for pembrolizumab plus chemotherapy versus chemotherapy alone. Results were most sensitive to changes in the extrapolation of event-free survival (EFS). All sensitivity and scenario analyses generated ICERs below the willingness-to-pay threshold of CHF100,000/QALY, and the PSA showed a 98.8% probability that the ICER would be below this threshold. Limitations Due to the limited follow-up period in the KEYNOTE-522 trial, EFS data were extrapolated over the lifetime horizon to inform transition probabilities. Extensive validation and scenario analyses ensured the results were robust. Conclusion The model demonstrated that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab was cost-effective versus chemotherapy alone in patients with high-risk, early-stage TNBC in Switzerland. Supplementary Information The online version contains supplementary material available at 10.1007/s41669-023-00445-8.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Favre-Bulle,

Huang,

Haiderali

et al. 2023

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…With 19.3 million new cases and 10 million deaths in 2020, cancer is a leading cause of premature death and a significant barrier to increasing life expectancy for the global population ( 1 , 2 ), and results in high social medical expenses and personal financial burden ( 3 , 4 ). To date, cancer remains a major public problem that threatens the health of the population.…”

Section: Introductionmentioning

confidence: 99%

Bibliometric analysis of global research on physical activity and sedentary behavior in the context of cancer

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveNumerous studies focusing on sedentary behavior (SB) and physical activity (PA) in the context of cancer have been reported in recent years. We analyzed and visualized studies on SB and PA in patients with cancer over the last 20 years using scientometric methods, to provide insights on gaps and deficiencies in the literature, and to inform future research guidelines.MethodsAll relevant studies in the field from 2001 to October 2022 were reviewed using bibliometric tools, including VOSviewer, Bibliometric online analysis platform, and biblioshiny, to determine the most influential countries, institutions, journals, and authors. We explored current research hotpots and potential research trends, based on keyword clustering and dynamic changes. Our research focuses on PA, SB, and cancer across the entire cancer continuum, from primary prevention to treatment to cancer survivorship.ResultsScientometric analysis identified 4,382 relevant manuscripts on SB and PA in the context of cancer, with a 10-fold increase in articles over the past 20 years. The United States, Canada, and Australia were the most influential countries. The journal, Supportive Care in Cancer, had the highest number of publications, while Clinical Oncology had the highest H-index. K.S. Courneya was the most influential author in this field, with the highest number of publications, total citations, and H-index. Keyword analysis revealed that current research is focused on PA and SB in patients with breast cancer, quality of life, and aerobic exercise. Future frontiers include cancer prehabilitation programs and cardiorespiratory fitness, and remote intervention and social support.ConclusionBy using bibliometrics, we conducted a comprehensive review of SB and PA in cancer-related studies. The current research focused on exercise and sedentariness in breast cancer patients and the role of PA in improving quality of life in survivorship. Emerging research foci were generally around cancer prehabilitation programs and remote intervention issues for PA. In addition, some publication deficits are noted: studies of PA and SB in less common cancers; the recommended doses and intensities of exercise for cancer; the timing of interventions for prehabilitation and the establishment of individualized exercise protocols. These deficiencies align with the needs for future research topics.

show abstract

“…The global incidence of breast cancer in women is estimated to reach as many as 3.2 million new cases annually by the year 2050 [ 2 ]. Breast cancer is the fifth leading cause of cancer deaths worldwide and is estimated to have caused 684,996 deaths in 2020 [ 3 ]. Incidence rates for breast cancer far exceed those of other cancers in both transitioned (55.9 per 100,000) and transitioning (29.7 per 100,000) countries [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

A systemmatic literature review on indirect costs of women with breast cancer

Mohammadpour

Soleimanpour

Javan‐Noughabi

et al. 2022

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Introduction The rising incidence of breast cancer places a financial burden on national health services and economies. The objective of this review is to present a detailed analysis of the research and literature on indirect costs of breast cancer. Methods English literature databases from 2000 to 2020 were searched to find studies related to the objective of the present review. Study selection and data extraction was undertaken independently by two authors. Also, quality assessment was done using a checklist designed by Stunhldreher et al. Results The current study chose 33 studies that were eligible from a total of 2825 records obtained. The cost of lost productivity due to premature death based on human capital approach ranged from $22,386 to $52 billion. The cost burden from productivity lost due to premature death based on friction cost approach ranged from $1488.61 to $4,518,628.5. The cost burden from productivity lost due to morbidity with the human capital approach was reported as $126,857,360.69 to $596,659,071.28. The cost of lost productivity arising from informal caregivers with the human capital approach was $297,548.46 to $308 billion. Conclusion Evaluation of the existing evidence revealed the indirect costs of breast cancer in women to be significantly high. This study did a thorough review on the indirect costs associated with breast cancer in women which could serve as a guide to help pick the appropriate method for calculating the indirect costs of breast cancer based on existing methods, approach and data. There is a need for calculations to be standardised since the heterogeneity of results in different domains from various studies makes it impossible for comparisons to be made among different countries.

show abstract

Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review

Cited by 14 publications

References 69 publications

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

Bibliometric analysis of global research on physical activity and sedentary behavior in the context of cancer

A systemmatic literature review on indirect costs of women with breast cancer

Contact Info

Product

Resources

About